Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Phosphate nephropathy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    10 result(s) found for: Phosphate nephropathy. Displaying page 1 of 1.
    EudraCT Number: 2011-001267-49 Sponsor Protocol Number: CL005_140 Start Date*: 2011-10-25
    Sponsor Name:ChemoCentryx, Inc
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX140-B in Diabetic Nephropathy
    Medical condition: Diabetic Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) CZ (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-001661-21 Sponsor Protocol Number: WP3.protocol.v7 Start Date*: 2022-02-08
    Sponsor Name:Herlev and Gentofte Hospital
    Full Title: Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - A Pilot Study
    Medical condition: Diabetic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10012687 Diabetic renal disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-004042-42 Sponsor Protocol Number: DEER Start Date*: 2014-06-19
    Sponsor Name:King’s College London [...]
    1. King’s College London
    2. Guy's and St Thomas NHS Foundation Trust
    Full Title: A study to investigate the potential renoprotective role of sodium-glucose transporter-2 (SGLT-2) antagonist Dapagliflozin in Type 2 diabetic patients with diabetic nephropathy
    Medical condition: Diabetic Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-003049-16 Sponsor Protocol Number: CL007_140 Start Date*: 2011-08-29
    Sponsor Name:ChemoCentryx, Inc
    Full Title: A Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Effect of CCX140-B on Albuminuria in Subjects with Type 2 Diabetes Mellitus
    Medical condition: Type 2 Diabetes Mellitus, nephropathy, albuminuria
    Disease: Version SOC Term Classification Code Term Level
    14.0 10014698 - Endocrine disorders 10012602 Diabetes mellitus (incl subtypes) HLT
    14.0 10038359 - Renal and urinary disorders 10027525 Microalbuminuria PT
    14.0 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    14.0 10038359 - Renal and urinary disorders 10001580 Albuminuria PT
    14.0 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2008-004099-26 Sponsor Protocol Number: 6.version,september2011 Start Date*: 2009-12-10
    Sponsor Name:Departmnet of nephrology
    Full Title: Randomised trial on combined effects of dual blockade of the renin angiotensin system and phosphate binding in diabetic and non-diabetic patients with impaired renal function.
    Medical condition: decreased renal function (CKD II-IV), creatinin clearance 15-90 ml/min
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    18.0 10038359 - Renal and urinary disorders 10013231 Disorder kidney LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-004447-80 Sponsor Protocol Number: SFN-2-2019 Start Date*: 2021-05-19
    Sponsor Name:University Clinic of Nephrology and Hypertension, Regional Hospital Holstebro
    Full Title: The effects of SGLT2-inhibition in patients with type 2 diabetes and chronic kidney disease on renal hemodynamics, kidney function and vasoactive hormones
    Medical condition: Type 2 diabetes with chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10045250 Type II diabetes mellitus with renal manifestations LLT
    23.1 100000004857 10076408 Chronic kidney disease stage 1 LLT
    23.1 100000004857 10076410 Chronic kidney disease stage 3 LLT
    23.1 100000004857 10076411 Chronic kidney disease stage 4 LLT
    23.1 100000004857 10076409 Chronic kidney disease stage 2 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-006516-31 Sponsor Protocol Number: IT1850071 Start Date*: 2008-06-03
    Sponsor Name:University Hospital Freiburg, represented by the Executive Medical Director (LÄD)
    Full Title: Triple arm, prospective-randomised multi centre study phase IV to evaluate calcineurin inhibitor reduced, steroid free immunosuppression after renal transplantation in low-risk patients (HARMONY-St...
    Medical condition: One year follow-up in patients after receiving renal transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-012213-22 Sponsor Protocol Number: PHX1149-PROT306 Start Date*: 2009-11-11
    Sponsor Name:Phenomix Corporation
    Full Title: A Randomized, Double-Blind, Placebo- and Sitagliptin-Controlled, Multi-Center Study to Evaluate Safety and Efficacy of Dutogliptin in Type 2 Diabetes Mellitus Subjects With Moderate and Severe Rena...
    Medical condition: Type II Diabetes Mellitus in subjects with Moderate and Severe Renal Impairment including subjects on Hemodialysis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10045250 Type II diabetes mellitus with renal manifestations LLT
    Population Age: Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-018285-23 Sponsor Protocol Number: 18102009 Start Date*: 2010-06-04
    Sponsor Name:King's College London [...]
    1. King's College London
    2. Guy's and St.Thomas' NHS Foundation Trust
    Full Title: Effect of active vitamin D treatment on arterial stiffness and albuminuria in patients with type 2 diabetes and stage 3 chronic kidney disease
    Medical condition: Diabetic kidney disease.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004857 10009119 Chronic renal failure LLT
    17.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-003025-10 Sponsor Protocol Number: VIVID Start Date*: 2011-11-08
    Sponsor Name:King's College London [...]
    1. King's College London
    2. Guy's and St Thomas NHS Foundation Trust
    Full Title: Effect of active vitamin-D treatment on left ventricular hypertrophy in patients with type-2 diabetes and stage-3 chronic kidney disease.
    Medical condition: Left ventricular hypertrophy, type 2 diabetes, chronic kidney disease.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    20.0 10007541 - Cardiac disorders 10047295 Ventricular hypertrophy PT
    20.0 100000004861 10012612 Diabetes mellitus non insulin-dep LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 13:15:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA